On 16 June 2026, the Ministry of Health and Family Welfare amended the Drugs Rules, 1945 to ban over‑the‑counter (OTC) sales of all syrups, including cough syrups. The move aims to curb misuse, overdoses and irrational drug use, especially among children.
Key Developments
- All liquid formulations (syrups) now require a valid prescription.
- Cough lozenges, pills and tablets remain available OTC.
- Pharmacists and retailers were notified immediately; messages were also sent in Telugu to reach remote areas of Telangana.
- Stakeholders expressed mixed views on enforcement and potential loopholes.
Important Facts
Several active ingredients in common cough‑and‑cold syrups—such as chlorpheniramine, phenylephrine, terbutaline, levosalbutamol and salbutamol—pose safety risks when taken without medical supervision.
Pharmacist Uday Kumar of Mor Chemists warned that consumers expect instant relief and may resist prescription requirements. He also highlighted the larger problem of counterfeit and unbranded medicines, which are hard to detect and often require months of laboratory testing.
Dealer Neelesh Kanodia distinguished codeine‑based syrups from regular ones, noting that codeine‑containing products are already largely sold on prescription. He doubts the blanket rule will survive long‑term, but expects continued restriction on codeine syrups.
The TCDA quickly circulated the new directive to about 39,000 pharmacies in the state, including roughly 18,000 in Hyderabad.
Exam Relevance
This policy touches upon multiple GS papers:
- GS1 (Polity): Role of the central ministry and state associations in implementing health regulations.
- GS3 (Health & Social Justice): Public‑health impact of prescription‑only rules, drug safety, and the challenge of counterfei